E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Raised blood pressure in pregnancy as a result of abnormal function of the placenta |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036485 |
E.1.2 | Term | Pre-eclampsia |
E.1.2 | System Organ Class | 10036585 - Pregnancy, puerperium and perinatal conditions |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To examine if the use of low-dose aspirin starting at 11-14 weeks gestation in women at increased risk for pre-eclampsia (high blood pressure) can reduce the incidence and severity of this complication. |
|
E.2.2 | Secondary objectives of the trial |
To examine if the use of low-dose aspirin can reduce the incidence of early delivery due to complications from high blood pressure, growth restricted babies, stillbirth or neonatal complications related to high blood pressure, rate of neonatal admission, the incidence of placental separation and spontaneous preterm delivery before 34 weeks and 37 weeks. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age ≥18 years • Singleton pregnancies • Live fetus at 11-13 weeks of gestation • High-risk for preterm preeclampsia will be defined at 11-13 weeks by the algorithm combining maternal history, biophysical findings (mean arterial blood pressure and uterine artery Dopplers) and biochemical factors (PAPP-A and PlGF) • English, Italian, Spanish and French speaking (otherwise NHS Trust interpreters, in the UK will be used) • Informed and written consent |
|
E.4 | Principal exclusion criteria |
• Multiple pregnancies • Pregnancies complicated by major fetal abnormality identified at the 11-13 weeks assessment • Women taking low-dose aspirin regularly (administration must have ceased >28 days prior to randomisation) • Women who are unconscious or severely ill, those with learning difficulties, and serious mental illness • Bleeding disorders such as Von Willebrand’s disease • Peptic ulceration • Hypersensitivity to aspirin or already on long term non-steroidal anti-inflammatory medication • Age < 18 years • Concurrent participation in another drug trial or at any time within the previous 28 days • Any other reason the clinical investigators think will prevent the potential participant from complying with the trial protocol |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of preterm pre-eclampsia (< 37 weeks). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Once delivered, data on pregnancy outcome, including labour onset, gestational age at delivery, mode of delivery, development of hypertension in pregnancy, neonatal birth weight and gender, and other obstetrics complications, will be collected from the hospital maternity records or their general medical practitioners. In addition, the obstetric records of women with pre-existing or pregnancy associated hypertension will be examined to determine if the condition is pre-eclampsia requiring delivery before 37 weeks' gestation. |
|
E.5.2 | Secondary end point(s) |
Secondary end points: 1. Incidence of early preeclampsia (<34 weeks) and total preeclampsia (at any gestation); 2. Birth weight below the 3rd, 5th and 10th centile; 3. Stillbirth or neonatal death due to any cause; 4. Stillbirth or neonatal death ascribed to preeclampsia or fetal growth restriction; 5. Stillbirth or neonatal death in association with maternal or neonatal bleeding; 6. Rate of neonatal intensive care unit admission; 7. Composite measure of neonatal mortality and morbidity; 8. Placental abruption (clinically or on placental examination); 9. Spontaneous preterm delivery <34 weeks and <37 weeks. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Once delivered, data on pregnancy outcome, including labour onset, gestational age at delivery, mode of delivery, development of hypertension in pregnancy, neonatal birth weight and gender, and other obstetrics complications, will be collected from the hospital maternity records or their general medical practitioners. In addition, the obstetric records of all women with pre-existing or pregnancy associated hypertension will be examined to determine if the condition is pre-eclampsia requiring delivery before 34 weeks' gestation.
Neonatal outcomes will be collected from the Special Care Baby Unit/Neonatal Intensive Care Unit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study for individual participants will be defined as 30 days after delivery of the baby or 30 days after the EDD date, whichever is the latter. The end of the study as a whole will be defined as the point at which the last participant (n=1,684) has fulfilled the above definition and details of their complete pregnancy outcome have been collected. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 31 |